TRIM family proteins: Retroviral restriction and antiviral defence

Nature Reviews Microbiology

Volumn 3, Issue 10, 2005, Pages 799-808

  Nisole, Sébastien ^a   Stoye, Jonathan P ^b   Saïb, Ali ^a  

^a CNRS   (France)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROMYELOCYTIC LEUKEMIA PROTEIN; TRIPARTITE PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; NUCLEAR PROTEIN; PML PROTEIN, HUMAN; PROTEIN; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR; TRIM22 PROTEIN, HUMAN; TRIM32 PROTEIN, HUMAN; TRIM5(ALPHA) PROTEIN, RHESUS MONKEY; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ANTIVIRAL ACTIVITY; APOPTOSIS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; HUMAN; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN MOTIF; RETROVIRUS; REVIEW; VIRUS REPLICATION; ALTERNATIVE RNA SPLICING; ANIMAL; CHEMISTRY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE;

ALTERNATIVE SPLICING; ANIMALS; HUMANS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTEIN STRUCTURE, TERTIARY; PROTEINS; REPRESSOR PROTEINS; RETROVIRIDAE; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; VIRUS REPLICATION;

EID: 27244444559     PISSN: 17401526     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrmicro1248     Document Type: Review

References (128)

1. Isaacs, A. & Burke, D. C. Mode of action of interferon. Nature 182, 1073-1074 (1958).
2. Medzhitov, R., Preston-Hurlburt, P. & Janeway, C. A. Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388, 394-397 (1997).
3. Goff, S. P. Retrovirus restriction factors. Mol. Cell 16, 849-859 (2004).
4. Harris, R. S. & Liddament, M. T. Retroviral restriction by APOBEC proteins. Nature Rev. Immunol. 4, 868-877 (2004).
5. Voinnet, O. Induction and suppression of RNA silencing: Insights from viral infections. Nature Rev. Genet. 6, 206-220 (2005).
6. Gao, G., Guo, X. & Goff, S. P. Inhibition of retroviral RNA production by ZAP, a CCCH-type zinc finger protein. Science 297, 1703-1706 (2002).
7. Reddy, B. A., Kloc, M. & Etkin, L. The cloning and characterization of a maternally expressed novel zinc finger nuclear phosphoprotein (xnf7) in Xenopus laevis. Dev. Biol. 148, 107-116 (1991).
8. Reymond, A. et al. The tripartite motif family identifies cell compartments. EMBO J. 20, 2140-2151 (2001).
9. Ota, T. et al. Complete sequencing and characterization of 21,243 full-length human cDNAs. Nature Genet. 36, 40-45 (2004).
10. Strausberg, R. L. et al. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc. Natl Acad. Sci. USA 99, 16899-16903 (2002).
11. Miyamoto, K. et al. RING finger, B-box, and coiled-coil (RBCC) protein expression in branchial elpithelial cells of Japanese eel, Anguilla japonica. Eur. J. Biochem. 269, 6152-6161 (2002).
12. C. elegans Sequencing Consortium. Genome sequence of the nematode C. elegans: A platform for investigating biology. Science 282, 2012-2018 (1998).
13. Saurin, A. J., Borden, K. L., Boddy, M. N. & Freemont, P. S. Does this have a familiar RING? Trends Biochem. Sci. 21, 208-214 (1996).
14. Levering, R. et al. Identification and preliminary characterization of a protein motif related to the zinc finger. Proc. Natl Acad. Sci. USA 90, 2112-2116 (1993).
15. Borden, K. L. RING domains: Master builders of molecular scaffolds? J. Mol. Biol. 295, 1103-1112 (2000).
16. Freemont, P. S. RING for destruction? Curr. Biol. 10, R84-R87 (2000).
17. Joazeiro, C. A. & Weissman, A. M. RING finger proteins: Mediators of ubiquitin ligase activity. Cell 102, 549-552 (2000).
18. Xu, L. et al. BTBD1 and BTBD2 colocalize to cytoplasmic bodies with the RBCC/tripartite motif protein, TRIM5δ. Exp. Cell Res. 288, 84-93 (2003).
19. Trockenbacher, A. et al. MID1, mutated in Opitz syndrome, encodes an ubiquitin ligase that targets phosphatase 2A for degradation. Nature Genet. 29, 287-294 (2001).
20. σ for proteolysis and promotes breast tumour growth. Nature 417, 871-875 (2002).
21. Horn, E. J. et al. RING protein Trim32 associated with skin carcinogenesis has anti-apoptotic and E3-ubiquitin ligase properties. Carcinogenesis, 25, 157-167 (2004).
22. Vichi, A., Payne, D. M., Pacheco-Rodriguez, G., Moss, J. & Vaughan, M. E3 ubiquitin ligase activity of the trifunctional ARD1 ADP-ribosylation factor domain protein 1). Proc. Natl Acad. Sci. USA 102, 1945-1950 (2005).
23. Reddy, B. A., Etkin, L. D. & Freemont, P. S. A novel zinc finger coiled-coil domain in a family of nuclear proteins. Trends Biochem. Sci. 17, 344-345 (1992).
24. Borden, K. L. et al. In vivo and in vitro characterization of the B1 and B2 zinc-binding domains from the acute promyelocytic leukemia protooncoprotein PML. Proc. Natl Acad. Sci. USA 93, 1601-1606 (1996).
25. Cao, T., Borden, K. L., Freemont, P. S. & Etkin, L. D. Involvement of the rfp tripartite motif in protein-protein interactions and subcellular distribution. J. Cell Sci. 110, 1563-1571 (1997).
26. Borden, K. L. et al. The solution structure of the RING finger domain from the acute promyelocytic leukaemia proto-oncoprotein PML. EMBO J. 14, 1532-1541 (1995).
27. Peng, H. et al. Reconstitution of the KRAB-KAP-1 repressor complex: A model system for defining the molecular anatomy of RING-B box-coiled-coil domain-mediated protein-protein interactions. J. Mol. Biol. 295, 1139-1162 (2000).
28. 2+-release channels). Trends Biochem. Sci. 22, 193-194 (1997).
29. Henry, J., Mather, I. H., McDermott, M. F. & Pontarotti, P. B30.2-like domain proteins: Update and new insights into a rapidly expanding family of proteins. Mol. Biol. Evol. 15, 1696-1705 (1998).
30. Vernet, C. et al. Evolutionary study of multigenic families mapping close to the human MHC class I region. J. Mol. Evol. 37, 600-612 (1993).
31. Hilton, D. J. et al. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc. Natl Acad. Sci. USA 95, 114-119 (1998).
32. Aasland, R., Gibson, T. J. & Stewart, A. F. The PHD finger: Implications for chromatin-mediated transcriptional regulation. Trends Blochem. Sci. 20, 513-59 (1995).
33. Le Douarin, B. et al. A possible involvement of TIF1 α and TIL 1 β in the epigenetic control of transcription by nuclear receptors. EMBO J. 15, 6701-6715 (1996).
34. Venturini, L. et al. TIF 1 γ, a novel member of the transcriptional intermediary factor 1 family. Oncogene 18, 1209-1217 (1999).
35. The French FMF Consortium. A candidate gene for familial Mediterranean fever Nature Genet. 17, 25-31 (1997).
36. Quaderi, N. A. et al. Opitz G/BBB syndrome, a defect of midline development, is due to mutations in a new RING finger gene on Xp22. Nature Genet. 17, 285-291 (1997).
37. Frosk, P. et al. Limb-girdle muscular dystrophy type 2H associated with mutation in TRIM32, a putative E3-ubiquitin-ligase gene. Am. J. Hum. Genet. 70, 663-672 (2002).
38. Avela, K. et al. Gene encoding a new RING-B-box-coiled-coil protein is mutated in mulibrey nanism. Nature Genet. 25, 298-301 (2000).
39. de The, H. et al. The PML-RARα fusion mRNA generated by the t(15; 17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66, 675-684 (1991).
40. Kakizuka, A. et al. Chromosomal translocation t(15; 17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML. Cell 66, 663-674 (1991).
41. Goddard, A. D., Borrow, J., Freemont, P. S. & Solomon, E. Characterization of a zinc finger gene disrupted by the t(15; 17) in acute promye
42. Takahashi, M., Inaguma, Y., Hiai, H. & Hirose, F. Developmentally regulated expression of a human 'finger'-containing gene encoded by the 5′ half of the ret transforming gene. Mol. Cell Biol. 8, 1853-1856 (1988).
43. Le Douarin, B. et al. The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBO J. 14, 2020-2033 (1995).
44. Stremlau, M. et al. The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys. Nature 427, 848-853 (2004).
45. Hatziioannou, T., Perez-Caballero, D., Yang, A., Cowan, S. & Bieniasz, P. D. Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIMα. Proc. Natl Acad. Sci. USA 101, 10774-10779 (2004).
46. Keckesova, Z., Ylihen, L. M. & Towers, G. J. The human and African green monkey TRIM5α genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc. Natl Acad. Sci. USA 101, 10780-10785 (2004).
47. Perron, M. J. et al. TRIM5α mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc. Natl Acad. Sci. USA 101, 11827-11832 (2004).
48. Yap, M. W., Nisole, S., Lynch, C. & Stoye, J. P. Trim5α protein restricts both HIV-1 and murine leukemia virus. Proc. Natl Acad. Sci. USA 101, 10786-10791 (2004).
49. Tissot, C. & Mechti, N. Molecular cloning of a new interferon-induced factor that represses human immunodeficiency virus type 1 long terminal repeat expression. J. Biol. Chem. 270, 14891-14898 (1995).
50. Hofmann, T. G. & Will, H. Body language: The function of PML nuclear bodies in apoptosis regulation. Cell Death Differ. 10, 1290-1299 (2003).
51. Kentsis, A. et al. The RING domains of the promyelocytic leukemia protein PML and the arenaviral protein Z repress translation by directly inhibiting translation initiation factor elF4E. J. Mol. Biol. 312, 609-623 (2001).
52. Pearson, M. et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406, 207-210 (2000).
53. Wang, Z. G. et al. Role of PML in cell growth and the retinoic acid pathway. Science 279, 1547-1551 (1998).
54. Lin, H. K., Bergmann, S. & Pandolfi, P. P. Cytoplasmic PML function in TGF-β signalling. Nature 431, 205-211 (2004).
55. Koken, M. H. et al. The t(15; 17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J. 13, 1073-1083 (1994).
56. Muller, S., Matunis, M. J. & Dejean, A. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J. 17, 61-70 (1998).
57. Ishov, A. M. et al. PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J. Cell Biol. 147, 221-234 (1999).
58. Sternsdorf, T., Jensen, K. & Will, H. Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1. J. Cell Biol. 139, 1621-1634 (1997).
59. Dyck, J. A. et al. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 76, 333-343 (1994).
60. Weis, K. et al. Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocytic leukemia cells. Cell 76, 345-356 (1994).
61. Zhu, J., Chen, Z., Lallemand-Breitenbach, V. & de The, H. How acute promyelocytic leukaemia revived arsenic. Nature Rev. Cancer 2, 705-713 (2002).
62. Zhu, J. et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc. Natl Acad. Sci. USA 94, 3978-3983 (1997).
63. 3-induced PML or PML/retinoic acid receptor α degradation. J. Exp. Med. 193, 1361-1371 (2001).
64. Boutell, C., Orr, A. & Everett, R. D. PML residue lysine 160 is required for the degradation of PML induced by herpes simplex virus type 1 regulatorv protein ICP0. J. Virol, 77, 8686-8694 (2003).
65. Borden, K. L. Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies. Mol. Cell Biol. 22, 5259-5269 (2002).
66. Stadler, M. et al. Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. Oncogene 11, 2565-2573 (1995).
67. Chelbi-Alix, M. K. et al. Induction of the PML protein by interferons in normal and APL cells. Leukemia 9, 2027-2033 (1995).
68. Lavau, C. et al. The acute promyelocytic leukaemia-associated PML gene is induced by interferon. Oncogene 11, 871-876 (1995).
69. Katze, M. G., He, Y. & Gale, M. Jr. Viruses and interferon: A fight for supremacy. Nature Rev. Immunol. 2, 675-687 (2002).
70. Chelbi-Alix, M. K., Quignon, F., Pelicano, L., Koken, M. H. & de The, H. Resistance to virus infection conferred by the interferon-induced promyelocytic leukemia protein. J. Virol. 72, 1043-1051 (1998).
71. Asper, M. et al. Inhibition of different Lassa virus strains by α and γ interferons and comparison with a less pathogenic arenavirus. J. Virol. 78, 3162-3169 (2004).
72. Turelli, P. et al. Cytoplasmic recruitment of INI1 and PML on incoming HIV preintegration complexes: Interference with early steps of viral replication. Mol. Cell 7, 1245-1254 (2001).
73. Bell, P., Montaner, L. J. & Maul, G. G. Accumulation and intranuclear distribution of unintegrated human immunodeficiency virus type 1 DNA. J. Virol. 75, 7683-7691 (2001).
74. 3 enhances retroviral reverse transcription and counteracts Ref1 antiviral activity. J. Virol. 77, 3167-3180 (2003).
75. Regad, T. et al. PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator. EMBO J. 20, 3495-3505 (2001).
76. Meiering, C. D. & Linial, M. L. The promyelocytic leukemia protein does not mediate foamy virus latency in vitro. J. Virol. 77, 2207-2213 (2003).
77. Borden, K. L., Campbell Dwyer, E. J. & Salvato, M. S. An arenavirus RING (zinc-binding) protein binds the oncoprotein promyelocyte leukemia protein (PML) and relocates PML nuclear bodies to the cytoplasm. J. Virol. 72, 758-766 (1998).
78. Blondel, D. et al. Rabies virus P and small P products interact directly with PML and reorganize PML nuclear bodies. Oncogene 21, 7957-7970 (2002).
79. Maul, G. G., Guldner, H. H. & Spivack, J. G. Modification of discrete nuclear domains induced by herpes simplex virus type 1 immediate early gene 1 product (ICPO). J. Gen. Virol. 74, 2679-2690 (1993).
80. Everett, R. D. & Maul, G. G. HSV-1 IE protein Vmw110 causes redistribution of PML. EMBO J. 13, 5062-5069 (1994).
81. Chelbi-Alix, M. K. & de The, H. Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene 18, 935-941 (1999).
82. Muller, S. & Dejean, A. Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption. J. Virol. 73, 5137-5143 (1999).
83. Boutell, C., Sadis, S. & Everett, R. D. Herpes simplex virus type 1 immediate-early protein ICP0 and is isolated RING finger domain act as ubiquitin E3 ligases in vitro. J. Virol. 76, 841-850 (2002).
84. Hagglund, R. & Roizman, B. Characterization of the novel E3 ubiquitin ligase encoded in exon 3 of herpes simplex virus-1-infected cell protein 0. Proc. Natl Acad. Sci. USA 99, 7889-7894 (2002).
85. Boutell, C. & Everett, R. D. The herpes simplex virus type 1 (HSV-1) regulatory protein ICP0 interacts with and ubiquitinates p53. J. Biol. Chem. 278, 36596-36602 (2003).
86. Gu, H. & Roizman, B. The degradation of promyelocytic leukemia and Sp100 proteins by herpes simplex virus 1 is mediated by the ubiquitin-conjugating enzyme UbcH5a. Proc. Natl Acad. Sci. USA 100, 8963-8968 (2003).
87. Lopez, P., Jacob, R. J. & Roizman, B. Overexpression of promyelocytic leukemia protein precludes the dispersal of ND10 structures and has no effect on accumulation of infectious herpes simplex virus 1 or its proteins. J. Virol. 76, 9355-9367 (2002).
88. Chee, A. V., Lopez, P., Pandolfi, P. P. & Roizman, B. Promyelocytic leukemia protein mediates interferon-based anti-herpes simplex virus 1 effects. J. Virol. 77, 7101-7105 (2003).
89. Parkinson, J. & Everett, R. D. αherpesvirus proteins related to herpes simplex virus type 1 ICP0 affect cellular structures and proteins. J. Virol. 74, 10006-10017 (2000).
90. Lilly, F. Fv-2: Identification and location of a second gene governing the spleen focus response to Friend leukemia virus in mice. J. Natl Cancer Inst. 45, 163-169 (1970).
91. Hartley, J. W., Rowe, W. P. & Huebner, R. J. Host-range restrictions of murine leukemia viruses in mouse embryo cell cultures. J. Virol. 5, 221-225 (1970).
92. DesGroseillers, F. & Jolicoeur, P. Physical mapping of the Fv-1 tropism host range determinant of BALB/c murine leukemia viruses. J. Virol. 48, 685-696 (1983).
93. Kozak, C. A. & Chakraborti, A. Single amino acid changes in the murine leukemia virus capsid protein gene define the target of Fv1 resistance. Virology 225, 300-305 (1996).
94. Stoye, J. P. Fv1, the mouse retrovirus resistance gene. Rev. Sci. Tech. 17, 269-277 (1998).
95. Best, S., Le Tissier, P., Towers, G. & Stoye, J. P. Positional cloning of the mouse retrovirus restriction gene Fv1. Nature 382, 826-829 (1996).
96. Cordonnier, A., Casella, J.-F. & Heidmann, T. Isolation of novel human endogenous retrovirus-like elements with foamy virus-related pol sequence. J. Virol. 69, 5890-5897 (1995).
97. Goff, S. P. Operating under a Gag order: A block against incoming virus by the Fv1 gene. Cell 86, 691-693 (1996).
98. Benit, L. et al. Cloning of a new murine endogenous retrovirus, MuERV-L, with strong similarity to the human HERV-L element and with a gag coding sequence closely related to the Fv1 restriction gene. J. Virol. 71, 5652-5657 (1997).
99. Towers, G. et al. A conserved mechanism of retrovirus restriction in mammals. Proc. Natl Acad. Sci. USA 97, 12295-12299 (2000).
100. Besnier, C. et al. Characterization of murine leukemia virus restriction in mammals. J. Virol. 77, 13403-13406 (2003).
101. Hofmann, W. et al. Species-specific, postentry barriers to primate immunodeficiency virus infection. J. Virol. 73, 10020-10028 (1999).
102. Besnier, C., Takeuchi, Y. & Towers, G. Restriction of lentivirus in monkeys. Proc. Natl Acad. Sci. USA 99, 11920-11925 (2002).
103. Cowan, S. et al. Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc. Natl Acad. Sci. USA 99, 11914-11919 (2002).
104. Munk, C., Brandt, S. M., Lucero, G. & Landau, N. R. A dominant block to HIV-1 replication at reverse transcription in simian cells. Proc. Natl Acad. Sci USA 99, 13843-13848 (2002).
105. Yap, M. W., Nisole, S. & Stoye, J. P. A single amino acid change in the SPRY domain of human Trim5α leads to HIV-1 restriction. Curr. Biol. 15, 73-78 (2005).
106. Stremlau, M., Perron, M., Welikala, S. & Sodroski, J. Species-specific variation in the B30.2(SPRY) domain of TRIM5α determines the potency of human immunodeficiency virus restriction. J. Virol. 79, 3139-3145 (2005).
107. b congenic mice. Cancer Res. 53, 3433-3438 (1993).
108. Sawyer, S. L., Wu, L. I., Emerman, M. & Malik, H. S. Positive selection of primate TRIM5α identifies a critical species-specific retroviral restriction domain. Proc. Natl Acad. Sci. USA 102, 2832-2837 (2005).
109. Song, B. et al. The B30.2(SPRY) domain of the retroviral restriction factor TRIM5α exhibits lineage-specific length and sequence variation in primates. J. Virol. 79, 6111-6121 (2005).
110. Jolicoeur, P. The Fv-1 gene of the mouse and its control of murine leukemia virus replication. Curr. Top. Microbiol. Immunol. 86, 67-122 (1979).
111. Duran-Troise, G., Bassin, R. H., Rein, A. & Gerwin, B. I. Loss of Fv-1 restriction in Balb/3T3 cells following infection with a single N tropic murine leukemia particle. Cell 10, 479-488 (1977).
112. Yap, M. W. & Stoye, J. P. Intracellular localisation of Fv1. Virology 307, 76-89 (2003).
113. Nisole, S., Lynch, C., Stoye, J. P. & Yap, M. W. A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. Proc. Natl Acad. Sci. USA 101, 13324-13328 (2004).
114. Sayah, D. M., Sokolskaja, E., Berthoux, L. & Luban, J. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 430, 569-573 (2004).
115. Luban, J., Bossolt, K. L., Franke, E. K., Kalpana, G. V. & Goff, S. P. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 73, 1067-1078 (1993).
116. Gamble, T. R. et al. Crvstal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell 87, 1285-1294 (1996).
117. Towers, G. J. et al. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nature Med. 9, 1138-1143 (2003).
118. Forshey, B. M., von Schwedler, U., Sundquist, W. I. & Aiken, S. C. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J. Virol. 76, 5667-5677 (2002).
119. Dodding, M. P., Bock, M., Yap, M. W. & Stoye, J. P. Capsid processing requirements for abrogation of Fv1 and ref1 restriction. J. Virol. 79, 10571-10577 (2005).
120. Mortuza, G. B. et al. High-resolution structure of a retroviral capsid hexameric amino-terminal domain. Nature 431, 481-485 (2004).
121. Berthoux, F., Sebastian, S., Sokolskaja, E. & Luban, J. Lv1 inhibition of human immunodeficiency virus type 1 is counteracted by factors that stimulate synthesis or nuclear translocation of viral cDNA. J. Virol. 78, 11739-11750 (2004).
122. Nisole, S. & Saib, A. Early steps of retrovirus replicative cycle. Retrovirology 1, 9 (2004).
123. Fridell, R. A., Harding, F. S., Bogerd, H. P. & Cullen, B. R. Identification of a novel human zinc finger protein that specifically interacts with the activation domain of lentiviral Tat proteins. Virology 209, 347-357 (1995).
124. Geiss, G. K. et al. Cellular transciptional profiling in influenza A virus-infected lung epithelial cells: The role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc. Natl Acad. Sci. USA 99, 107313-10741 (2002).
125. Wang, Y. et al. TRIM45, a novel human RBCC/TRIM protein, inhibits transcriptional activities of EIK-1 and AP-1. Biochem. Biophys. Res. Commun. 323, 9-16 (2004).
126. Bjorndal, A. S., Szekely, L. & Elgh, F. Fools, virus infection inversely correlates with the overall expression levels of promyelocytic leukaemia (PML) protein in cultured cells. BMC Microbiol. 3, 6 (2003).
127. Bonilla, W. V. et al. Effects of promyelocytic leukemia protein on virus-host balance. J. Virol. 76, 3810-3818 (2002).
128. Djavani, M. et al. Role of the promyelocytic leukemia protein PML in the interferon sensitivity of lymphocytic choriomeningitis virus. J. Virol. 75, 6204-6208 (2001).